Grifols (GRFS)
(Delayed Data from NSDQ)
$6.38 USD
+0.11 (1.75%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.38 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value D Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GRFS 6.38 +0.11(1.75%)
Will GRFS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GRFS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GRFS
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
GRFS: What are Zacks experts saying now?
Zacks Private Portfolio Services
GRFS or ZTS: Which Is the Better Value Stock Right Now?
Here's Why Grifols (GRFS) Is a Great 'Buy the Bottom' Stock Now
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Other News for GRFS
Grifols SA’s Related Party Transactions: Navigating Conflicts of Interest and Investor Concerns
Grifols 2023 Annual Report on Form 20-F filed with the SEC
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
Grifols reportedly looking to appoint independent directors
ATUS, ATHE and GRFS among pre-market losers